Molecular Imaging Services, Inc. (MIS) is a privately held company with headquarters in Newark, Delaware. MIS specializes in Cardiac PET and PET/CT in-office cardiology imaging solutions. The MIS comprehensive support approach redefines the turnkey model with unparalleled clinical, operational and reimbursement resources and solutions. With the support of our Medical Advisor - Gary Heller, MD, - we have solidified physician education and quality assurance vital to your successful transition to a 1st Class PET program.
According to Merriam-Webster a turnkey job is: “A job or contract in which the contractor agrees to complete the work of building and installation to the point of readiness for operation or occupancy.” MIS is committed to going beyond this widely accepted definition to provide a comprehensive and ongoing support program for our partners.
We understand that it is important to properly evaluate an opportunity and provide a high-quality operational start up, but MIS strives to go beyond to provide ongoing solutions and ensure long term success. MIS achieves this by providing access to a team of expert clinical and operational professionals that provide comprehensive solutions for the duration of the relationship.
MIS will analyze your PET opportunity and ensure a successful transition as you add Cardiac PET or PET/CT to your patient management options. MIS solutions factor in people and processes, efficient workflows, practice analytics and unparalleled clinical expertise to support your practice. As industry experts, MIS staff are focused on the clinical advantages of PET and PET/CT today while preparing for new isotopes and procedures in the developmental pipeline.
As an example of our mission to provide unparalleled solutions and keep our partners at the forefront of Cardiac PET imaging, MIS has developed the Myocardial Blood Flow 360 (MBF-360) program. With support from MIS, MBF can be added to an existing pharmacologic stress Cardiac PET perfusion protocol enhancing service to the medical community and without increasing radiation exposure to the patient. MIS provides a comprehensive approach to MBF, anchored by noted cardiologist Gary Heller, MD, PhD, which includes peer-to-peer training, technical instruction, MBF software, billing assistance and ongoing support.
One of the advantages of Cardiac PET cited in the ASNC/SNMMI Joint Statement is its ability to perform Myocardial Blood Flow (MBF) assessment, which can provide clinically important diagnostic information to the physician. MBF and Myocardial Flow Reserve (MFR), sometimes referred to as Coronary Flow Reserve (CFR), have come to the forefront as more clinics routinely utilize Rubidium 82 Cardiac PET. The use of MBF and MFR calculations during a cardiac PET stress test can assist the interpreting physician by providing additional quantification, helping further characterize the perfusion data. Myocardial flow reserve (MFR) constitutes the ratio of MBF during maximal coronary vasodilatation to resting MBF and is therefore impacted by both rest and stress flow. MFR represents the relative reserve of the coronary circulation and can be characterized in each vascular territory. Calculating the flow values, which are achieved by producing a dynamic image of the radiotracer entering the heart, adds more detail to the entirety of the test, and provides more information than perfusion images alone.
This webinar includes an expert assessment of the considerations that inspired the ASNC/SNMMI Position Statement on The Clinical Indications for Myocardial Perfusion PET, as well as a review practical solutions for developing a first-class PET program. The speakers share some of the challenges in an actual program including the installation process, operational considerations, reimbursement and billing, clinical education, and technical proficiency. They will review how a ‘Comprehensive Solutions Approach’ to the most common impediments to adding PET to a clinical practice helped overcome these challenges.
Mark Wilson | EVP, Sales & Business Development
visit the site
Cardiac PET perfusion imaging has been gaining acceptance in the nuclear cardiology community because of higher diagnostic accuracy, faster protocols for patient convenience, lower radiation exposure, and less artifact resulting in fewer false positive studies. Despite these advantages, patient motion during the PET acquisition does occur and can lead to an inconclusive or false positive result. This discussion will describe how it occurs, the appearance of motion on images, and the potential impact on interpretation.
Dr. Heller has more than 30 years of experience in clinical cardiology and nuclear cardiology. He established the first PET program in Connecticut that focused on cardiac perfusion, myocardial viability assessment and cardiac sarcoid.